Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 The reported safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results